These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30730267)

  • 1. Immunotherapy: a 10-year anniversary issue.
    Gregg M
    Immunotherapy; 2019 Feb; 11(2):61-62. PubMed ID: 30730267
    [No Abstract]   [Full Text] [Related]  

  • 2. Introduction: Cancer Immunology Special Issue-Immunotherapy.
    Kawakami Y
    Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
    [No Abstract]   [Full Text] [Related]  

  • 3. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
    Wang Y; Ma R; Liu F; Lee SA; Zhang L
    Front Immunol; 2018; 9():374. PubMed ID: 29556232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1/PD-L1 in disease.
    Kuol N; Stojanovska L; Nurgali K; Apostolopoulos V
    Immunotherapy; 2018 Feb; 10(2):149-160. PubMed ID: 29260623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STING signaling: a key to therapeutic tumor immunity.
    Foote JB; Emens LA
    Immunotherapy; 2018 Jul; 10(9):729-731. PubMed ID: 30008260
    [No Abstract]   [Full Text] [Related]  

  • 6. Microbiota-Regulated Outcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis.
    Patel J; Crawford JM
    Biochemistry; 2018 Feb; 57(6):901-903. PubMed ID: 29350031
    [No Abstract]   [Full Text] [Related]  

  • 7. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.
    Liu B; Song Y; Liu D
    J Hematol Oncol; 2017 Dec; 10(1):174. PubMed ID: 29195503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hiding in Plain Sight: Soluble Immunomodulatory Receptors.
    Dahal LN; Schwarz H; Ward FJ
    Trends Immunol; 2018 Oct; 39(10):771-774. PubMed ID: 30195467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer: any room left for immunotherapies?
    Baxevanis CN; Fortis SP; Perez SA
    Immunotherapy; 2019 Feb; 11(2):69-74. PubMed ID: 30727800
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
    van Dam LS; de Zwart VM; Meyer-Wentrup FA
    Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Part I: Checkpoint inhibitors in cancer therapy.
    Daud AI
    Immunotherapy; 2016 Jun; 8(6):675-6. PubMed ID: 27197535
    [No Abstract]   [Full Text] [Related]  

  • 13. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
    Šmahel M
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory mechanisms of PD-L1 expression in cancer cells.
    Shi Y
    Cancer Immunol Immunother; 2018 Oct; 67(10):1481-1489. PubMed ID: 30120503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visualizing microbiome-immune system interplay.
    Siebert JC; Görg C; Palmer B; Lozupone C
    Immunotherapy; 2019 Feb; 11(2):63-67. PubMed ID: 30730269
    [No Abstract]   [Full Text] [Related]  

  • 16. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
    Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
    Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Part II: Checkpoint inhibitors in cancer therapy.
    Daud AI
    Immunotherapy; 2016 Jun; 8(7):761-2. PubMed ID: 27349974
    [No Abstract]   [Full Text] [Related]  

  • 18. Coinhibitory Pathways in Immunotherapy for Cancer.
    Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
    Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunoimaging and targeting treatment in an immunocompetent murine model of triple-negative breast cancer using radiolabeled anti-programmed death-ligand 1 monoclonal antibody.
    Pang X; Liu M; Wang R; Liao X; Yan P; Zhang C
    J Labelled Comp Radiopharm; 2018 Sep; 61(11):826-836. PubMed ID: 29923634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical applications of PD-L1 bioassays for cancer immunotherapy.
    Liu D; Wang S; Bindeman W
    J Hematol Oncol; 2017 May; 10(1):110. PubMed ID: 28514966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.